

CURRICULUM VITAE

Careen K. Tang

Work Address:

Research Bldg. E512
Department of Oncology
Georgetown University Medical Center
Lombardi Comprehensive Cancer Center
3970 Reservoir Rd.
Washington D.C. 20007
(202) 687-0361 or 687-0342
e-mail: tangc@georgetown.edu

Citizenship: U.S. Citizen

EDUCATION:

9/84 - 5/89 Ph. D. In Chemistry/Molecular Biology
The Johns Hopkins University, Baltimore, Maryland.
Research Advisor: Dr. David E. Draper

8/80 - 5/83 B.S. in Chemistry,
University of Maryland, College Park, Maryland.

PROFESSIONAL EXPERIENCE:

5/02 –present Associate Professor Department of Oncology/Biochemistry. Georgetown University Lombardi Cancer Center, Washington D.C..

2006-present Course Director for Department of Biochemistry & Cellular Biology MS and Ph.D. programs.

2005-present Tumor Biology Oversight Committee Member/Admission, Academic Review Tumor Biology Ph.D. and Master Programs.

9/95 – 4/02 Assistant Professor Department of Oncology/Biochemistry. Georgetown University Lombardi Cancer Center, Washington D.C.

11/92 - 9/95 Research Associate, Department of Biochemistry.
Georgetown University Lombardi Cancer Center, Washington D.C.

6/89 -10/92 IRTA fellow
NIH/NICHD/CBMB, Bethesda, Maryland. (Dr. Richard Klausner).

HONORS:

- 2006** The significance of our research was high lighted in the annual report “Transformation” by Cancer Research and Prevention foundation
- 2003** Article published in *Mol Cancer Res.* (2003) was selected for the **cover figure**.
- 2002** Presentation in Era of Hope was selected for media interview and reported on local news paper.
- 2002** Article published in *International Journal of Cancer* (2002) was selected for the **cover figure**.
- 2001** **Travel Award** for 2001 AACR high rated abstract.
- 2000** Article published in *Cancer research*, (2000) 60:3081-3087 referred to as **Top News** in *Cancer Weekly* August 1, 2000.
- 1999** Article published in *Cancer Research*, (1999) 59: 5315-5322. referred to as **Top News** in *Cancer Weekly*, 1999.
- 1995** **Outstanding Poster** for 1995 AACR annual meeting.
- 1994** **Travel Award** by Bristol-Myers Oncology Division for AACR Presenter of Outstanding Abstract.
- 1993** **First Place** for postdoctoral division of the eighth annual research day competition, Georgetown University Medical Center.
- 1989-1992** **IRTA Fellowship**, NIH/NICHD/CBMB.
- 1989** Article published in *Cell*, (1989) Vol. 57, 531-536, was selected as **one of 1989 best article in Cell**.
- 1988** **Ernest M. Marks Award** for excellence in teaching and research, The Johns Hopkins University.
- 1988** The presented work in Cold Spring Harbor meeting was selected for the **cover figure** on the abstract book.
- 1983** **Academic Honors List**, University of Maryland, College Park, MD.

PATENTS:

- U.S. Patent** PCT/US98/23279 (Atty Docket No. 009/094/SAP).
- U.S. Patent** PCT/US03/05404

PUBLIC SOCIETIES:

American Association for Cancer Research
Georgetown University- Society for Medical Women Faculty (SMWF)

PUBLIC SERVICE:

Study Section/Grant & Manuscript Reviews:

- 2010 - present Ad Hoc Member, NIH/NCI ZRG1 OTC-L Cancer Drug Development and Therapeutics (CDDT) Study Section
- 2010 - present Ad Hoc Member, NIH/NCI Drug Discover and Molecular Pharmacology (DMP) Study Section
- 2010 Member, USAMRMC Grant Review for Breast Cancer Research Program, “Era of Hope Scholar Award” Study Section
- 2010 Member, USAMRMC Grant Review for Breast Cancer Research Program,

- “Detection, Diagnosis, and Prognosis” Study Section.
- 2009 Member, NIH/NCI Oncology-2 Translational Clinical IRG [ZRG1 OTC-K (58)]
- 2009 Member, The Susan G. Komen Breast Cancer Foundation Targeted Therapeutics Study Section TT5
- 2007 - 2009 Member of Review Panel for National Institutes of Health/NCI “Discovery and Development P01 Special Emphasis Panel” ZCA1 GRB-P.
- 2007 - 2009 Member, USAMRMC Grant Review for Breast Cancer Research Program, Study Section Clinical & Experimental therapeutics #3 Study Section (CET-3)
- 2007 Member, USAMRMC Grant Review for Breast Cancer Research Program, Study Section- Clinical & Experimental Therapeutics (CET-3)
- 2003 - 2007 Full Member, National Institutes of Health/NCI, “Tumor Progression and Metastasis” (TPM) Study Section.
- 2006 Member, USAMRMC Grant Review for Breast Cancer Research Program, Study Section-Molecular Genetics (MGN-2)
- 2005 Member of Review Panel for National Institutes of Health/NCI Special Emphasis Panel-ZRG1 (ZCA1 GRB-1 (J1)) NCI SPORE (Specialized Programs of Research Excellence) in Lung and Genitourinary Cancers.
- 2005 Review panel member for National Agency for Science, Technology and Research’s (A*STAR) Biomedical Research Council (BMRC) in Singapore.
- 2004, 2005 Member, USAMRMC Grant Review for Breast Cancer Research Program, Study Section-Cell Biology#2 (CBY-2)
- 2004 Member of National Institutes of Health/NCI, ZRG1 F09 (20) Study Section.
- 2003 Member of National Institutes of Health/NCI, Special Emphasis Panel-ZRG1 CPA-03 Study section.
- 2001 - 2003 Ad Hoc Member, National Institutes of Health/NCI, “Pathology B” (Path B) Study Section.
- 2002 Grant reviewer for Cancer Research, UK.
- 2002 Member of National Institutes of Health/NCI, Radiation Study Section Special Emphasis Panel.
- 2001, 2002 Member, USAMRMC Grant Review for 2001 Breast Cancer Research Program, Study Section-Cell Biology#22 (CBY-2)
- 1999 - 2002 Member, The Susan G. Komen Breast Cancer Foundation Grant Review Study Section
- 1999 Member, USAMRMC for 1999 Breast Cancer Research Program, Study Section-Molecular Genetics (MGN-2)
- 1997 - 1998 Grant reviewer for The Israel Science Foundation
- 1997 - present Reviewer for Scientific Journals; J.B.C., Oncogene, Cancer Research, Clinical Cancer Research, Breast Cancer Research and Treatment, etc.

INVITED PRESENTATIONS:

- 2009 “Tob Supresses Breast Cancer Tumorigenesis” PO meeting, Department of Surgery, Georgetown University Medical Center.
- 2009 “Network of EGFRvIII in Breast Cancer” Faculty presentation, Department of Oncology Georgetown University Medical Center.
- 2008 “Cross-talk Between EGFRvIII and CXCR4 in Breast Cancer” The World Cancer

- Congress meeting
- 2007 “Tob-1 in Breast Cancer” Hong Kong International Cancer Congress, 4th International Think Tank Forum and 4th Annual Meeting of Centre for Cancer Research (Nov. 2007 in Hong Kong).
- 2006 “EGFRvIII in Breast Cancer” Genetic, Cellular and Microenvironmental Determinants of Tumor Progression and Metastasis workshop for NIH/NCI TPM
- 2004 “The Role of EGFRvIII in Breast Cancer” Department of Biochemistry, Georgetown University Medical Center.
- 2003 “The Role of EGFR variant in Prostate Cancer” CapCure retreat. NY, NY.
- 2002 “Ribozyme Targeting the Novel Fusion Junction of EGFRvIII in Breast Cancer” Era of Hope, the Department of Defense Breast Cancer Research Program.
- 2001 “Clinical Significance of EGFRvIII in Breast Cancer” George Washington University, Department of Pharmacology, Washington DC.
- 2001 “The Role of EGFRvIII in Breast Cancer”, 6th World Congress on Advances in Oncology and 4th International Symposium on Molecular Medicine (2001), Hersonissos, Crete, Greece.
- 2001 “The Pathological Role of EGFRvIII in Breast Cancer” The Johns Hopkins University Oncology Center, Breast Cancer Research Program, Baltimore, MD.
- 2000 “Ribozyme Targeting the Novel Fusion Junction of EGFRvIII in Breast Cancer” 2000 National Grant Conference, The Susan G. Komen Breast Cancer Foundation, Dallas, TX.
- 1999 “Elucidate the Role of EGFRvIII in Human Breast Cancer” 1999 National Grant Conference, The Susan G. Komen Breast Cancer Foundation
- 1998 “The Pathogenic Role of ErbB-4 in Human Breast Cancer” Breast Cancer Symposium-“Think Tank 8”, Tobago, W. India.
- 1997 “The Biological Effects of Ribozyme-mediated Down-regulation of ErbB-4 in Breast Cancer” Era of Hope, the Department of Defense Breast Cancer Research Program.

GEORGETOWN UNIVERSITY SERVICE:

GU Committees:

- 2006-present Tumor Biology Program Oversight Committee Member for Department of Oncology.
- 2005-present LCCC Tissue Scientific Review Committee.
- 2004-present Tumor Biology Master's Oversight committee member for Department of Oncology.
- 2002-present Institutional Biosafety Committee.
- 2006-2008 University Conflict of Interest Committee.
- 2004 Participate and help for planning of RDIG activity for academic year 2004-2005.
- 2001 Research Infrastructure Enhancements Working Group for Department of Oncology.

Chair or Member of Ph.D. Thesis Committees for the following students:

- 2009-present Member of Thesis Committee for Department of Biochemistry graduate student Jessica Keffer
- 2008-present Chair of Thesis Committee for Department of Oncology Graduate students

- Rebecca Nakles & Sonia Rosenfeld
- 2008-2010 Chair of Thesis Committee for Department of Oncology MD/Ph.D. student David Solomon
- 2006-2009 Chair of Thesis Committee for Department of Oncology Graduate students Anne Miermont, Lynn Neilson & Jennifer Webster
- 2005-2009 Member of Thesis Committee for Department of Microbiology graduate student Sarah Linnstaedt
- 2005-2007 Member of Thesis Committee for Department of Oncology graduate student John Tylor Lahusen
- 2000-2003 Member of Thesis Committee for Department of Oncology graduate student Jacqueline Ruttimann.
- 2000-2001 Member of Thesis Committee for Department of Oncology graduate student James Welch.

TEACHING ACTIVITIES:

Course director:

- 2008-present Course director for BCHB-517 Cancer Biology
- 2007-present Course co-director for CBIO-539 Molecular/ Cell Biology
- 2007-2009 Course co-director for CBIO-562 Molecular/ Cell Biology: In-depth Analysis

Lectures:

- 2008- present Lecturer for BCHB-517 Cancer Biology.
- 2007- present Lecturer for CBIO-539 Molecular & Cell Biology.
- 2007- present Lecturer for CBIO-562 Molecular/ Cell Biology: In-depth Analysis.
- 2005- present Lecturer for Cellular and Molecular Aspects of the Transformed Cell, Oncology/Tumor Biology, TBIO 508.
- 2004- present Lecturer for Core Concepts of Biochemistry Molecular Biology, BCHB-513.
- 2004- present Lecturer for Modern Methods in Molecular Biology, Pharmacology/Biochemistry 528.
- 2004- present Lecturer for Modern Methods in Molecular Biology, BCHB 526.
- 2000- 2004 Lecturer for Interdisciplinary Research Survey Course, MICB-505.
- 2003 Lecturer for Principles and Practice of Molecular Therapy, TBIO-554
- 2000- 2001 Lecturer for Mechanism of Molecular & Cellular Control, BCHB-529

Graduate Student Ph.D. Dissertation Mentor:

- 2006 - 2009 Thesis mentor for Department of Oncology TBIO graduate student Massod Rahimi
- 2005 - 2007 Thesis mentor for Department of Biochemistry graduate student John G. Foulke.
- 1997 - 1999 Thesis co-mentor for Department of Physiology graduate student Rose (XiaoHong) Yang

Post-Doctoral Fellows/MD who did research in Dr. Tang's Lab:

- 2010-present Polly Lin, Ph.D.
- 2007-2010 Kai-Ling Huang, Ph.D.
- 2005-2008 Hua Su, Ph.D. & Shenglin Chen, Ph.D.
- 2002-2005 Hong Yu, MD.

2003-2004 Ming Yan, M.D., Ph.D. and Wei Han, M.D.
2001-2003 Yang Zhang, M.D., Tao Zhang, Ph.D.
2001-2002 UDC faculty Dr. Norman Kondo for UDC/Georgetown LCC Partner in Cancer Research Training, Education and Outreach Program.
2000-2001 Honori Kunisue, M.D., Ge Lou, M.D., Rui Min, M.D.
1999-2001 Hong Ge, MD. Ph.D., Xunyi Luo, M.D., Xiaoqi Gong, M.D.,

Medical School Summer Research Fellows Mentored:

2009 Timothy Chang (Case Western Reserve University School of Medicine)
2007 Timothy Chang (Case Western Reserve University School of Medicine)
1997 Jennifer Payne (Georgetown University School of Medicine)
1995 Caroline Wailbel (Georgetown University School of Medicine)

Ph.D. Candidates did research rotation in Tang's Lab.

2009 Department of Biochemistry graduate student Kevin Chandler
2007 Department of Biochemistry graduate student Ricardo Martinez Zamudio
2005 Department of Biochemistry graduate student John Foulke.
2005 Department of Oncology TBIO graduate students Massod Rahimi & Sonia Menin Rosenfield
2004 Department of Biochemistry graduate students Amani Batarseh.

M.S. Students Thesis Research Mentor:

2010 Department of Biochemistry graduate student Yu-Ju Lee
2010 Department of Biochemistry graduate student Haw-Ning Yang
2009 Department of Biochemistry graduate student Elias J. Sobrino Najul
2009 Department of Oncology Master Program student Ifeyinwa Obiorah
2006-2007 Department of Biochemistry graduate student Ryan Tochihara.
2007 Department of Biochemistry graduate student Tariq Arif
2005-2006 Department of Oncology Master Program student Kathleen Batley.
2004-2005 Department of Biochemistry graduate student Lauren E. Thompson.
2004-2005 Department of Oncology Master Program student Dina Shammaa.
2001-2002 Department of Biochemistry Master Program student Aybike Birerdinc.

International Student Thesis Research Mentor:

2010 Chinese University of Hong Kong "DRAM Program" student Sisi Liu
2008 Chinese University of Hong Kong "DRAM Program" student Linda Shen
2007 Chinese University of Hong Kong "DRAM Program" student Crystal Ng
2006 Chinese University of Hong Kong "DRAM Program" student Gary Ching Ka Wai

Minority Students Research Program Mentored:

2001- 2002 Research Course Mentor for Marc Program student Francisco J. Guenaga.
2001 Cure program student Claudelia Williams.

Pre-medical and Pre-graduate Students Mentored:

1996-1998 Kevin Brennan, Melissa Milan, Mathew Fred, Jonna Derbenwick, Alice Xiao-Zheng Wu and Achena Oates.

SCHOLARSHIP AND RESEARCH:

A. PUBLICATIONS

Original Articles: (*Corresponding author)

Massod Rahimi, Kai-Ling Huang and ***Careen K. Tang**. "Inhibition of Growth and Invasion of Human Cancer Cells Expressing EGFR Mutants by 3,3'-Diindolylmethane (DIM)" (2010) *Cancer Letters*, 295(1):59-68.

Takayuki Otani, Toshihiro Hashizume, Tadahiro Nagaoka, Tomoko Fukuda, **Careen K. Tang**, David S. Salomon and Masaharu Seno "IgG hinge-tag useful for design of biologically active soluble ErbBs (2010) *Biotechnology Letters*. 32:361-366.

Zhang Yang, Hua Su, Massod Rahimi, Ryan Tochihara, & ***Careen K. Tang**, "EGFRvIII-Induced Estrogen-Independence, Tamoxifen-Resistance Phenotype correlates with PgR expression and Modulation of Apoptotic Molecules in Breast Cancer" (2009) *International Journal of Cancer* Apr 27;125(9):2021-2028.

Sean O'Malley, Hua Su, Tao Zhang, Hong Ge, Crystal Mei Ng, Hong Yu and ***Careen K. Tang** "TOB Suppresses Breast Cancer Tumorigenesis" (2009) *International Journal of Cancer*, Oct 15;125(8):1805-13.

Rahimi, M., George, J. and ***Tang, CK**. "EGFR variant-mediated invasion by enhancing CXCR4 expression through transcriptional and post-translational mechanisms". (2009) *Int. J of Cancer*, Oct 14. 126(8):1850-60.

Hong Yu, Xiaoqi Gong, Xunyi Luo, Zhang Yang, Hong Ge, Wei Han, Rebecca Slack, Baljit Singh and ***Careen K. Tang** "Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways. EGFRvIII mediated constitutively activated and sustained signaling pathways" (2008) *Cancer Biology & Therapy*, Nov 24;7(11).

Hua Su & ***Tang C.K.** "Genetic alterations in esophageal carcinoma" (2007) *Recent Progress in Cancer Research by Transworld Research Network*, p37-58.

Massod & ***Tang C.K.** "The chemokine receptor, CXCR4, and human cancer" (2007) *Recent Progress in Cancer Research by Transworld Research Network*, p131-156.

Wei Han, Tao Zhang, Hong Yu, John G. Foulke and ***Careen K. Tang**. "Hypophosphorylation of Residue Y1045 Leads to Defective Down-regulation of EGFRvIII," (2006) *Cancer Biology & Therapy*, 26;5(10), 1361-8.

Yves A. De Clerck, Bernard E. Weissman, Dihua Yu, Ramon Parsons, Menashe Bar-Eli, Pradip Roy-Burman, Victoria L. Seewaldt, Anne E. Cress, Lucia R. Languino, Surinder K. Batra, **Careen K. Tang**, Shije Sheng, Wen-Tien Chen, Srikumar Chellappan, Shi-Yuan Cheng, Stephan Ladisch, James B. McCarthy, Lisa M. Coussens and Michael B. Cohen. (2006) "Tumor

Progression and Metastasis from Genetic to Microenvironmental Determinants". *Cancer Biology & Therapy*, 5(12), 1279-1728.

Traxler P., Allegrini PR., Brandt R., Brueggen J., Cozens R., Lane HA., McWheehy P., Mestan J., Meyer T., **Tang C.**, Wartmann M., Wood J., and Caravatti G. "AEE788 – a dual family EGFR/ErbB2 and VEGFR tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity"(2005) *Cancer Res.* 2004 Jul 15;64(14):4931-41.

***Tang C.K.** "Role of Epidermal Growth Factor Receptor in Breast Carcinoma" (2004) *Handbook of Immunohistochemistry and In Situ Hybridization of Human Carcinomas*, (ed. M.A.Hayat). Vol.1, p415-424.

Luo X.Y, Gong X.Q. and ***Tang C.K.** "Suppression of EGFRvIII-mediated proliferation and tumorigenesis of breast cancer cells by ribozyme". (2003) *International Journal of Cancer*, May 10;104(6):716-21.

Tsai MS, Shamon-Taylor LA, Mehmi I, ***Tang CK**, Lupu R. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. (2003) *Oncogene* Feb 6;22(5):761-8.

Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, ***Tang C**, Lupu R. "Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo". (2003) *Mol Cancer Res* Jan;1(3):165-75.

Hong Ge, Xiaoqi Gong and ***Careen K. Tang**. "High Incidence of Co-expression of EGFRwt and EGFRvIII Transcripts in Human Invasive Breast Cancer Tissue By Laser Capture Microdissection/RT-PCR" (2002) *International Journal of Cancer*, 98:357-361.

Ge Hong & ***Tang C.K.** "Detection of EGFRwt and EGFRvIII in Human Breast Cancer" (2002) *Recent Research Developments in Cancer by Transworld Research Network*, Vol. 4: 419-427.

Yang X.H., Wei L., **Tang C.K.**, Mueller S. & Lippman M.E. "Overexpression of KAI1 Suppresses In Vitro Invasiveness and In vivo Metastasis in Breast Cancer Cells" (2001) *Cancer Research*, 61:5284-8.

***Tang C.K.** "The New Development of Class I Tyrosine Kinase Superfamily in Human Cancer" (2001) *Recent Research Developments in Cancer by Transworld Research Network*, Vol. 3, 267-273.

Kunisue H., Kurebayashi J., Otsuki T., **Tang C.K.**, Kurosumi M. Yamamoto S., Tanaka K., Shimizu N. and Sonoo H., Anti-"HER2 Antibody Enhances the Growth Inhibitory Effect of Anti-oestrogen on Breast Cancer Cells Expressing both Estrogen Receptors and HER2" (2000) *Br J Cancer*, 82(1):46-51.

Yang X.H., Wei L., **Tang C.K.**, Slack R., Montgomery E. & Lippman M.E. "KAI1 Protein Is Down-Regulated During The Progression of Human Breast Cancer" (2000) *Clinical Cancer Research*, 6(9): 3424-9.

- ***Tang C.K.**, Xiaoqi Gong, David K. Moscatello, Albert J. Wong & Lippman M.E., “EGFRvIII Enhances Tumorigenicity in Human Breast Cancer”. (2000) *Cancer Research*, 60:3081-3087.
- Hijazi MM, Thompson EW, **Tang C**, Coopman P, Torri JA, Yang D, Mueller SC, Lupu R. (2000) Heregulin Regulates the Actin Cytoskeleton and Promotes Invasive Properties in Breast Cancer Cell Lines. *Int J Oncol* 17(4): 629-41.
- ***Tang C.K.**, & Lippman M.E., “EGF Superfamily and Breast Cancer” (2000) *Breast Disease: A year Book Quarterly*.
- ***Tang C.K.** “EGFRvIII and Human Cancer” (2000) *Cancer Research Alert*, Oct: 52-54.
- Kurebayashi J., Otsuki T., **Tang C.K.**, Kurosumi M. Yamamoto S., Tanaka K., Mochizuki M., Nakamura H., & Sonoo H., “Isolation and Characterization of a New Human Breast Cancer Cell Line, KPL-4, Expressing the ErbB Family Receptors and Interleukin-6.” (1999) *British J. Cancer Research*, 79: 707-717.
- Biano C., Kannan S., Santis MD., Seno M., **Tang, C.K.**, Martinez-Lacaci I., Kim N., Wallace-Jones B., Lippman ME., Ebert A., Wechselberger C. and Salomon DS., “Cripto-1 Indirectly Stimulates the Tyrosine Phosphorylation of ErbB-4 Through a Novel Receptor”. (1999) *J.B.C.* 274: 8624-8629.
- ***Tang C.K.**, Wu X-Z. A., Milan M., Gong X.Q., Montgomery E. and Lippman M.E., “Ribozyme Mediated Down-regulation of ErbB-4 in Estrogen Receptor Positive Breast Cancer Cells Inhibits Proliferation both *in vitro* and *in vivo*.” (1999) *Cancer Research*, 59: 5315-5322.
- Lyndsay N. Harris, Li Yang, **Careen Tang**, Dajun Yang, and Ruth Lupu. Induction of Sensitivity to Doxorubicin and Etoposide by Transfection of MCF-7 Breast Cancer Cells with Heregulin β -2. (1998) *Clinical Cancer Research* 4: 1005-1012.
- ***Tang C.K.**, Goldstein D.J., Payne J., Czubayko F., Alimandi M., Wang L-M., Pierce J.H., & Lippman M.E., “ErbB-4 Ribozymes Abolish Neuregulin Induced Mitogenesis”. (1998) *Cancer Research*, 58: 3415-3422.
- Alimandi M., Wang L-M., Bottaro D., Lee C-C., Kuo A., Frankel M., Fedi P., **Tang C.K.**, Lippman M.E., & Pierce J.H., “Epidermal Growth Factor and Betacellulin Mediate Signal Transduction Through Coexpressed ErbB-2 and ErbB-3 Receptors”. (1997), *EMBO*, 16: 5608-5617.
- Tang C.K.** and Lippman M.E., “EGF Family Receptors and Their Ligands in Human Cancer”. (1997) *Hormones and Signaling*, Vol.1, (ed. B. W. O'Malley), pp.113-165.
- Lupu R., Cardillo M., Hijazi M., Harris L., Cho C., Pereze C., Rosenberg K., Yang DJ, & **Tang C.K.**, “The Significance of *Heregulin* in Breast Cancer Progression and Drug Resistance”. (1996) *Breast Cancer Research and Treatment* 38: 57- 66.

Tang C.K., Perez C., Grunt T., Cho C., Waibel C. & Lupu R., “Involvement of *Heregulin*β2 in the Acquisition of the Hormone-Independent Phenotype of Breast Cancer Cells”. (1996) *Cancer Research*, 56: 3350-3358.

Rouault T., Haile D., Downey W., Philpott C., **Tang C. K.**, Chin J., Paul I., Orloff D., Harford J., & Klausner R., “An Iron Sulfur Cluster Plays a Novel Regulatory Role In The Iron-Responsive Element Binding Protein” (1992) *Biometal* vol. 5, 131-140.

Haile D., Rouault T., **Tang C. K.**, Harford J., & Klausner R., “The Role of The Iron-sulfur Cluster In The Regulation of Iron Responsive Element Binding Protein” (1992) *Proc. Natl. Acad. Sci. USA*. Vol. 89, 7536-7540.

Tang C.K., Chin J., Harford J., Klausner R., & Rouault T., “Iron Regulates The Activity of The Iron-Responsive Element Binding Protein Without Changing Its Rate of Synthesis or Degradation”. (1992) *J. Biol. Chem.* Vol. 267 (34) 24466-24470.

Kaptain S., Downey W., **Tang C. K.**, Philpott C., Haile D., Harford J., Rouault T., & Klausner R., “A Regulated RNA Binding Protein Also Possesses Aconitase Activity” (1991) *Proc. Natl. Acad. Sci. USA*. Vol. 88, 10109-10113.

Rouault T., **Tang C. K.**, Kaptain S., Burgess W., Haile D., Samaniego F., McBride W., Harford J., & Klausner R., “Cloning of The cDNA Encoding An RNA Regulatory Protein --- The Human Iron-Responsive Element-Binding Protein” (1990) *Proc. Natl. Acad. Sci. USA*. Vol. 87, 7958-7962.

Tang C. K., & Draper D., “Evidence For Allosteric Coupling Between The Ribosome and Repressor Binding Sites of A Translationally Regulated mRNA” (1990) *Biochemistry*. Vol. 29, 4434-4439.

Tang C. K., & Draper D., (1989) “Unusual mRNA Pseudoknot Structure Is Recognized By A Protein Translational Repressor” *Cell*. Vol. 57, 531-536.

Draper D., **Tang C. K.**, & Vartikar J., (1988) “Ribosomal Protein S4 Recognizes Complex Messenger and Ribosomal RNA Structures.” *Molecular Biology of RNA* vol. 94 (ed. T. Cech) Alan R. Liss, Inc., New Your, N.Y.

Morita Y., Psiagianian R., **Tang C.K.** and Chiang P.K. (1982) “Inhibition of Histamine Release and Phosphotidylcholine Metabolism By 5'-deoxy-5'-isobutylthio-3-deazaadenosine.” *Biochemistry Pharmacologh.* 31, 2111-2113.

B) Research Grants:

I) Currently Active Support:

- 1) Principal Investigator: Careen K. Tang, Ph.D.
Agency: NIH/NCI; Grant #: CA106429-01

Type: RO1; Period: 07/01/05-6/30/11
Molecular Mechanisms of Blockage of ErbB receptors
OVERLAP: None.

- 2) Principal Investigator: Careen K. Tang, Ph.D.
Agency: Charles and Ella O. Latham;
Period: 07/01/10-6/30/11
OVERLAP: None.
- 3) Agency: Boehringer Ingelheim Pharmaceuticals, Inc.
Principal Investigator: Careen K. Tang
Dates of Project Period: 01/01/10- 12/31/11
OVERLAP: None.

II) Past Support:

- 1) Principal Investigator: Careen K. Tang, Ph.D.
Agency: NIH/NCI; Grant #: CA88871
Type: R01. Period: Sept. 1, 2001 to Aug. 30, 2006
OVERLAP: None.
- 2) Principal Investigator: Careen K. Tang, Ph.D.
Agency: Cancer Research & Prevention
The Role of coexpression of ErbB-2 with CXCR4 in initiation of breast cancer
Dates of Project Period: 07/15/06 - 07/14/08
OVERLAP: None.
- 3) Principal Investigator: Careen K. Tang, Ph.D.
Agency: DoD Prostate Cancer Research Program; Grant #: DAMD17-02-1-0061
Type: New Investigator Grant, Period: Feb. 1, 2002 to Feb. 28, 2005
- 4) Principal Investigator: Careen K. Tang, Ph.D.
Agency: Susan Komen Breast Cancer Foundation; Grant #: PDF0100380
Period: Dec. 1, 2001 to Nov. 30, 2004
- 5) Principal Investigator: Careen K. Tang, Ph.D.
Agency: DoD Breast Cancer Research Program; Grant #: DAMD17-99-1-9206
Type: Idea Grant, Period: July 1, 1999 to June, 30, 2003
- 6) Principal Investigator: Careen K. Tang, Ph.D.
Agency: Novartis
Type: Research Grant
Period: July 1, 2002 to Sept. 30, 2003
- 7) Principal Investigator: Peter Ramwell, Co-PI: Careen K. Tang, Ph.D.
Agency: NIH
Period: 2001 to 2002

- 8) Principal Investigator: Careen K. Tang, Ph.D.
Agency: Susan Komen Breast Cancer Foundation; Grant #: 9826
Type: Research Grant; Period: Dec. 1, 1998 to Nov. 30, 2001
- 9) Principal Investigator: Norman Wolmark, MD (NSABP), Subcontract to Careen K. Tang
Agency: NIH; Grant #: U10CA12027-30, CFDA #93.395
- 10) Principal Investigator: Careen K. Tang, Ph.D.
Agency: DoD Breast Cancer Research Program; Grant #: DAMD17-96-1-6031
Type: Career Development Grant (CDA); Period: July 1, 1996 to June, 30, 2000
- 11) Principal Investigator: Careen K. Tang, Ph.D.
Agency: Charles and Ella O. Latham Charitable;
Jan. 1, 1998 to Dec. 31, 1998